Matthew Meyerson Google Scholar: h-index, Total Citations, and Citation Map
Matthew Meyerson's h-index is 239 (482 i10-index, 404,098+ total citations across 380+ publications) according to Google Scholar as of November 2026. Matthew Meyerson is affiliated with Harvard Medical School.
Matthew Meyerson is a researcher affiliated with Harvard Medical School, specializing in Cancer biology, genetics, and drug discovery. Their work has been cited 404,098 times. This profile visualizes their global influence, highlighting strong citation networks in United States.
Matthew Meyerson's Citation Metrics
Bibliometric impact based on 380 indexed publications.
- H-Index
- 239
- i10-Index
- 482
- Total Citations
- 404,098
- Citing Countries
- 91
As of November 2026.
Matthew Meyerson has an h-index of 239 and 404,098 total citations across 380 publications, with research cited by institutions in 91 countries.
Download Exports (PNG, CSV, Poster)
Free Viewing Matthew Meyerson's citation map is always free. Pay once to download poster, PNG, and CSV files for offline use or your visa packet.
Global Impact Map
Visualizing the geographic distribution of institutions that have cited your work.
Starting…
Pins will appear here as institutions are resolved — no need to refresh.
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
200412,568
Top Citing Countries
Top Citing Institutions
Visa Evidence Package
Views and exports tuned for EB-1A, O-1A, and EB-2 NIW petitions. Sustained acclaim, geographic reach, and independent-citation filtering are the strongest evidence categories immigration adjudicators look for.
Significant Contributions
Auto-detected research lines — a seminal paper and the follow-up work building on it. Review and edit before using in a petition. Each Free PDF opens in a new tab — EB-1A organises this into the structure USCIS applies to Criterion 5 of 8 CFR § 204.5(h)(3)(v); EB-1B re-frames it under § 204.5(i)(3) (outstanding researcher); NIW presents it under prong 2 of Matter of Dhanasar.
1 citing papers could not be classified (no author data) — excluded from the percentages above.
The researcher established the critical link between EGFR mutations and clinical response to gefitinib in lung cancer, a foundational discovery published in Science.
The researcher established a foundational framework for characterizing mutational signatures in human cancer, providing a critical tool for understanding cancer etiology and evolution.
The researcher developed the Cancer Cell Line Encyclopedia to enable predictive modeling of anticancer drug sensitivity, a foundational resource published in Nature.
Citation trend (last 10 years)Click to expand
Citation Trend (Last 10 Years)
Related Guides
Learn how to use citation maps for your research and visa applications.
About Matthew Meyerson's research
Matthew Meyerson is a researcher in Cancer biology, genetics and and drug discovery at Harvard Medical School. Their work has been cited 404,098 times across 380 publications (h-index 239), according to Google Scholar.
Their most-cited work, “EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy” (2004), has accumulated 12,568 citations. Other influential works include “Signatures of mutational processes in human cancer” (2013) with 11,515 citations and “<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy” (2004) with 9,380 citations.
Citations of Matthew Meyerson's research come primarily from United States, China and United Kingdom, reflecting international research impact across 5+ countries. The interactive citation map above shows the full geographic distribution of the institutions citing this work.











